Abstract
Gallstones affect 20% of the Western population and will grow in clinical significance as obesity and metabolic diseases become more prevalent. Gallbladder removal (cholecystectomy) is a common treatment for diseases caused by gallstones, with 1.2 million surgeries in the US each year, each costing USD 10,000. Gallbladder disease has a significant impact on the logistics and economics of healthcare. We discuss the two most common presentations of gallbladder disease (biliary colic and cholecystitis) and their pathophysiology, risk factors, signs and symptoms. We discuss the factors that affect clinical care, including diagnosis, treatment outcomes, surgical risk factors, quality of life and cost-efficacy. We highlight the importance of standardised guidelines and objective scoring systems in improving quality, consistency and compatibility across healthcare providers and in improving patient outcomes, collaborative opportunities and the cost-effectiveness of treatment. Guidelines and scoring only exist in select areas of the care pathway. Opportunities exist elsewhere in the care pathway.
| Original language | English |
|---|---|
| Article number | 388 |
| Pages (from-to) | e388 |
| Number of pages | 18 |
| Journal | Medicina |
| Volume | 58 |
| Issue number | 3 |
| Early online date | 5 Mar 2022 |
| DOIs | |
| Publication status | Published (in print/issue) - 5 Mar 2022 |
Bibliographical note
G.D., M.M., B.S., P.G. and A.J.B. are supported by the European Union’s INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB), project: Centre for Personalised Medicine-Clinical Decision Making and Patient Safety. The views and opinions expressed in this paper do not necessarily reflect those of the European Commission or the Special EU Programmes Body (SEUPB).Funding Information:
G.D., M.M., B.S., P.G. and A.J.B. are supported by the European Union?s INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB), project: Centre for Personalised Medicine-Clinical Decision Making and Patient Safety. The views and opinions expressed in this paper do not necessarily reflect those of the European Commission or the Special EU Programmes Body (SEUPB).
Funding Information:
Funding: G.D., M.M., B.S., P.G. and A.J.B. are supported by the European Union’s INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB), project: Centre for Personalised Medicine-Clinical Decision Making and Patient Safety. The views and opinions expressed in this paper do not necessarily reflect those of the European Commission or the Special EU Programmes Body (SEUPB).
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Funding Information:
G.D., M.M., B.S., P.G. and A.J.B. are supported by the European Union?s INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB), project: Centre for Personalised Medicine-Clinical Decision Making and Patient Safety. The views and opinions expressed in this paper do not necessarily reflect those of the European Commission or the Special EU Programmes Body (SEUPB).
Funding Information:
Funding: G.D., M.M., B.S., P.G. and A.J.B. are supported by the European Union’s INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB), project: Centre for Personalised Medicine-Clinical Decision Making and Patient Safety. The views and opinions expressed in this paper do not necessarily reflect those of the European Commission or the Special EU Programmes Body (SEUPB).
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Funding Information:
Funding: G.D., M.M., B.S., P.G. and A.J.B. are supported by the European Union’s INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB), project: Centre for Personalised Medicine-Clinical Decision Making and Patient Safety. The views and opinions expressed in this paper do not necessarily reflect those of the European Commission or the Special EU Programmes Body (SEUPB).
Funding Information:
G.D., M.M., B.S., P.G. and A.J.B. are supported by the European Union’s INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB), project: Centre for Personalised Medicine-Clinical Decision Making and Patient Safety. The views and opinions expressed in this paper do not necessarily reflect those of the European Commission or the Special EU Programmes Body (SEUPB).
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Keywords
- gallbladder disease
- gallstones
- biliary colic
- cholecystitis
- clinical care
- cholelithiasis
- Gallbladder disease
- Gallstones
- Biliary colic
- Clinical care
- Cholecystitis
- Cholelithiasis
- Cholecystectomy
- Colic - diagnosis - etiology - therapy
- Humans
- Gallbladder Diseases - complications - surgery
- Cholecystitis - complications - surgery
- Quality of Life
- Cholecystitis/complications
- Gallbladder Diseases/complications
- Colic/diagnosis
